Breast Cancer Risk Among Male BRCA1 and BRCA2 Mutation Carriers

Overview

Journal J Natl Cancer Inst

Publisher Oxford University Press

Specialty Oncology

Date 2007 Nov 29

PMID 18042939

Citations 129

Authors

Yu Chuan Tai

Susan Domchek

Giovanni Parmigiani

Sining Chen

Affiliations

Soon will be listed here.

Abstract

Men who carry germline mutations in the BRCA2 gene have a higher risk of developing breast carcinoma than men in the general population. Men who carry germline mutations in the BRCA1 gene may also be at a higher risk for breast carcinoma, but this association is not as well established. We evaluated the risks of developing breast carcinoma for male BRCA1 and BRCA2 mutation carriers in the US population based on data from 1939 families with 97 male subjects with breast carcinoma that were collected from eight centers across the National Cancer Institute's Cancer Genetics Network. At all ages, the cumulative risks of male breast cancer were higher in both BRCA1 and BRCA2 mutation carriers than in noncarriers. The relative risks of developing breast cancer were highest for men in their 30s and 40s and decreased with increasing age. Both the relative and cumulative risks were higher for BRCA2 mutation carriers than for BRCA1 mutation carriers. The estimated cumulative risk of breast carcinoma for male BRCA1 mutation carriers at age 70 years was 1.2% (95% confidence interval [CI] = 0.22% to 2.8%) and for BRCA2 mutation carriers, 6.8% (95% CI = 3.2% to 12%).

Citing Articles

Quality-of-Life and Oncological Outcomes in Male Breast Cancer: Insights from an Extensive 20-Year Experience.

Ferrucci M, Milardi F, Passeri D, Pozzerle M, Cagol M, Saibene T Cancers (Basel). 2025; 17(5).

PMID: 40075676 PMC: 11899275. DOI: 10.3390/cancers17050829.

Therapeutic Management in Elderly Male Breast Cancer Patients: A Scoping Review.

Di Rito A, Grillo A, Carbonara R Curr Oncol Rep. 2025; 27(2):120-134.

PMID: 39826033 DOI: 10.1007/s11912-024-01629-z.

Effective Targeting of Glutamine Synthetase with Amino Acid Analogs as a Novel Therapeutic Approach in Breast Cancer.

Abdelsattar S, Al-Amodi H, Kamel H, Al-Eidan A, Mahfouz M, El Khashab K Int J Mol Sci. 2025; 26(1.

PMID: 39795937 PMC: 11720649. DOI: 10.3390/ijms26010078.

Sex differences in childhood cancer risk following ART conception: a registry-based study.

Oakley L, Kristjansson D, Munthe-Kaas M, Nguyen H, Lee Y, Hanevik H Hum Reprod. 2024; 40(2):382-390.

PMID: 39724532 PMC: 11788205. DOI: 10.1093/humrep/deae285.

Experience of urologists, oncologists and nurse practitioners with mainstream genetic testing in metastatic prostate cancer.

Vlaming M, Ausems M, Kiemeney L, Schijven G, van Melick H, Noordzij M Prostate Cancer Prostatic Dis. 2024; .

PMID: 39639158 DOI: 10.1038/s41391-024-00925-w.

References

Frank T, Deffenbaugh A, Reid J, Hulick M, Ward B, Lingenfelter B . Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol. 2002; 20(6):1480-90. DOI: 10.1200/JCO.2002.20.6.1480. View

Struewing J, Coriaty Z, Ron E, Livoff A, Konichezky M, Cohen P . Founder BRCA1/2 mutations among male patients with breast cancer in Israel. Am J Hum Genet. 1999; 65(6):1800-2. PMC: 1288396. DOI: 10.1086/302678. View

Thompson D, Easton D . Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. Am J Hum Genet. 2001; 68(2):410-9. PMC: 1235274. DOI: 10.1086/318181. View

Easton D, Steele L, Fields P, Ormiston W, Averill D, Daly P . Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12-13. Am J Hum Genet. 1997; 61(1):120-8. PMC: 1715847. DOI: 10.1086/513891. View

Parmigiani G, Berry D, Aguilar O . Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet. 1998; 62(1):145-58. PMC: 1376797. DOI: 10.1086/301670. View

Friedman L, Gayther S, Kurosaki T, Gordon D, Noble B, Casey G . Mutation analysis of BRCA1 and BRCA2 in a male breast cancer population. Am J Hum Genet. 1997; 60(2):313-9. PMC: 1712407. View

Stratton M, Ford D, Neuhasen S, Seal S, Wooster R, Friedman L . Familial male breast cancer is not linked to the BRCA1 locus on chromosome 17q. Nat Genet. 1994; 7(1):103-7. DOI: 10.1038/ng0594-103. View

Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J . Identification of the breast cancer susceptibility gene BRCA2. Nature. 1995; 378(6559):789-92. DOI: 10.1038/378789a0. View

Kraft P, Thomas D . Bias and efficiency in family-based gene-characterization studies: conditional, prospective, retrospective, and joint likelihoods. Am J Hum Genet. 2000; 66(3):1119-31. PMC: 1288146. DOI: 10.1086/302808. View

10.

Fay M, Pfeiffer R, Cronin K, Le C, Feuer E . Age-conditional probabilities of developing cancer. Stat Med. 2003; 22(11):1837-48. PMC: 1475950. DOI: 10.1002/sim.1428. View

11.

Risch H, McLaughlin J, Cole D, Rosen B, Bradley L, Fan I . Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. J Natl Cancer Inst. 2006; 98(23):1694-706. DOI: 10.1093/jnci/djj465. View

12.

Landis S, Murray T, Bolden S, Wingo P . Cancer statistics, 1999. CA Cancer J Clin. 1999; 49(1):8-31, 1. DOI: 10.3322/canjclin.49.1.8. View

13.

Sverdlov R, Barshack I, Bar Sade R, Baruch R, Dagan E, Feinmesser M . Genetic analyses of male breast cancer in Israel. Genet Test. 2001; 4(3):313-7. DOI: 10.1089/10906570050501579. View

14.

Couch F, Farid L, DeShano M, Tavtigian S, Calzone K, Campeau L . BRCA2 germline mutations in male breast cancer cases and breast cancer families. Nat Genet. 1996; 13(1):123-5. DOI: 10.1038/ng0596-123. View

15.

Csokay B, Udvarhelyi N, Sulyok Z, Besznyak I, Ramus S, Ponder B . High frequency of germ-line BRCA2 mutations among Hungarian male breast cancer patients without family history. Cancer Res. 1999; 59(5):995-8. View

16.

Chen S, Parmigiani G . Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol. 2007; 25(11):1329-33. PMC: 2267287. DOI: 10.1200/JCO.2006.09.1066. View

17.

Chen S, Iversen E, Friebel T, Finkelstein D, Weber B, Eisen A . Characterization of BRCA1 and BRCA2 mutations in a large United States sample. J Clin Oncol. 2006; 24(6):863-71. PMC: 2323978. DOI: 10.1200/JCO.2005.03.6772. View

18.

Sasco A, Lowenfels A . Review article: epidemiology of male breast cancer. A meta-analysis of published case-control studies and discussion of selected aetiological factors. Int J Cancer. 1993; 53(4):538-49. DOI: 10.1002/ijc.2910530403. View

19.

Chen S, Wang W, Broman K, Katki H, Parmigiani G . BayesMendel: an R environment for Mendelian risk prediction. Stat Appl Genet Mol Biol. 2006; 3:Article21. PMC: 2274007. DOI: 10.2202/1544-6115.1063. View

20.

Lynch H, Watson P, Narod S . The genetic epidemiology of male breast carcinoma. Cancer. 1999; 86(5):744-6. DOI: 10.1002/(SICI)1097-0142(19990901)86:5<744::AID-CNCR4>3.0.CO;2-G. View